PMAIP1 and melanoma: Here, enhancing NOXA levels, suppressed the anti-apoptotic actions of Mcl1 and override resistance to ABT-737, with Vorinostat [152], Vinblastine [371], Bortezomib [109], Dinaciclib [372] co-treatments in SCLC, CLL and melanoma cells.